Tivozanib

替伏扎尼

Report date: 2026/05/11 20:01:57
NME

Base Information

Drug NameTivozanib
Drug Alias Name替沃扎尼盐酸盐一水合物 (Aveo Pharmaceuticals/Kyowa Kirin)TivopathtivozanibumTivozanib hydrochloride monohydrate (Aveo Pharmaceuticals/Kyowa Kirin)Fotivda +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Vascular endothelial growth factor receptor 2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursWet age-related macular degeneration +[19] 
Global Approved IndicationsCarcinoma, Renal Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/08/24
Country/TerritoryCzechiaBahamasBelgium +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRecordatiRecordati Netherlands BVEusa Pharma +[6] 
Inactive CompaniesUtah State UniversityDana-Farber Cancer InstituteKyowa Kirin Co Ltd +[7] 
Active IndicationsBile Duct NeoplasmsBiliary Tract NeoplasmsCholangiocarcinoma +[4] 
Inactive IndicationsMetastatic breast cancerSolid tumoursWet age-related macular degeneration +[15] 

Other Information

ATC CodeL01EK03
Related LinksWikipediaDrugBankKEGG